Verastem reports encouraging early data for its oral KRAS G12D inhibitor in pancreatic cancer
- Verastem presented early results for its KRAS G12D inhibitor, studied in more than 200 patients with advanced solid tumors including metastatic pancreatic cancer and others.
- Other coverage describes anti-tumor activity and a manageable safety profile across pancreatic, colorectal and lung cancers.
- This summary rests on the public lead of a paywalled STAT piece plus secondary reports, so details are limited.
💡 Points
KRAS G12D in pancreatic cancer is the biggest open space after G12C, and early activity with clean liver safety is what the field needs to see. The competitive question is durability against other G12D programs, including those from large players. Registration-directed Phase 2 trials and Fast Track status give Verastem a credible path, but single-arm early data can flatter.
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer ↗